Study
Association between blood nicotinamide adenine dinucleotide levels and blood laboratory parameters at baseline and after nicotinamide mononucleotide supplementation in middle-aged healthy individuals: post hoc analysis of a randomized, double-blinded, placebo-controlled clinical trial.
A post hoc analysis of 80 healthy adults linked NMN-related NAD increases with small changes in red-cell measures, not clinical outcomes.
Summary Does NMN improve health-related blood markers in healthy middle-aged adults? Show / hide ↓
Researchers took a later look at data from a 60-day trial involving 80 healthy middle-aged adults. Participants took 300, 600 or 900 milligrams of NMN, a supplement intended to raise NAD, or an inactive placebo. NAD is a molecule cells use in energy processes. People whose NAD rose had tiny increases in haemoglobin, the oxygen-carrying protein in red blood cells, and in red blood cell counts. Other links were mixed, including higher levels of some blood fats and liver-related markers, so the results did not show a clear overall benefit.
What this means for you: This does not show that NMN improves health, energy or longevity. For deciding whether to buy NMN, you can ignore this study because it was small, short and looked at blood-test links rather than meaningful health outcomes.
weak evidenceThis was a post hoc analysis of a randomised, double-blind clinical trial in healthy middle-aged participants. The parent trial compared daily nicotinamide mononucleotide at 300, 600 or 900 mg with placebo for 60 days. The analysis included 80 people with a mean age of 49.4 years. Baseline blood NAD was 7.21 nM, with an interquartile range of 5.5 to 10.6 nM.
The analysis related NAD concentrations and NAD changes to routine laboratory parameters. Each 1 nM higher baseline NAD was associated with higher lymphocytes, triglycerides and liver enzymes, alongside lower neutrophils and high-density lipoprotein. Increases in NAD were associated with small increases in haemoglobin, red blood cells, mean corpuscular haemoglobin concentration and uric acid. For example, each 1 nM NAD increase was associated with a 0.027% increase in haemoglobin and a 0.025% increase in red blood cells.
These are associations from a secondary analysis, not proof that NMN improves oxygen delivery, health or longevity. No functional, disease or survival endpoint is reported. The mixed laboratory associations also do not support a simple claim that higher NAD produces uniformly favourable blood markers.
NMN-induced increases in blood NAD were associated with higher red-cell parameters, potentially indicating enhanced oxygen-carrying capacity.
This is a post hoc analysis of 80 people over 60 days. The outcomes were laboratory associations rather than clinical or functional measures, so causality and health relevance remain uncertain.
Cited by
1 encyclopedia entries reference this study.